Search Results
Search for other papers by Solène Castellnou in
Google Scholar
PubMed
Search for other papers by Patricia Bretones in
Google Scholar
PubMed
Search for other papers by Juliette Abeillon in
Google Scholar
PubMed
Search for other papers by Myriam Moret in
Google Scholar
PubMed
Search for other papers by Pauline Perrin in
Google Scholar
PubMed
Search for other papers by Karim Chikh in
Google Scholar
PubMed
Search for other papers by Véronique Raverot in
Google Scholar
PubMed
Introduction: Maternal TSH receptor antibodies (TRAbs) can cross the placenta and affect fetal and neonatal thyroid function. Maternal TSH receptor-blocking antibodies (TBAbs) are a rare cause of congenital hypothyroidism. Case Report: Following the discovery of a highly elevated TSH on her neonatal screening test, a 10-day-old girl with no familial history of thyroid disorder was referred to the pediatric endocrinology unit. Hypothyroidism was confirmed with a highly elevated TSH (817 mIU/L, reference range 0.4–3.1) and very low levels of FT4 (1.8 pmol/L, reference range 12–22). Anti-TPO antibodies were at 81 IU/mL (reference range <34), TRAbs at 1.7 IU/L (reference range <1.75), and thyroglobulin at 9.4 µg/L (reference range 3.5–77). The thyroid appeared normal on ultrasonography, and no radioiodine uptake was seen on the scintigraphy after the perchlorate discharge test. Concomitantly, a severe maternal hypothyroidism was discovered (TSH 224 mIU/L). The maternal ultrasound appeared normal, anti-TPO antibodies were moderately elevated, and TRAbs were at 3.2 IU/L. TBAbs activity was measured in the mother and her daughter, and a very high and similar blocking activity was observed in both patients (TBAbs 89%, reference range <10%). L-thyroxine treatment was introduced in the newborn and was successfully discontinued at 6.5 months of age, as the TBAbs activity decreased. Conclusion: We report herein a case of transient congenital hypothyroidism with a normal neonatal TRAbs level. In case of maternal TBAbs, similar activity of maternal TBAbs must be expected in the neonate, independently of the neonatal level of TRAbs.
Search for other papers by Matthieu Bosset in
Google Scholar
PubMed
Search for other papers by Maxime Bonjour in
Google Scholar
PubMed
Search for other papers by Solène Castellnou in
Google Scholar
PubMed
Search for other papers by Zakia Hafdi-Nejjari in
Google Scholar
PubMed
Search for other papers by Claire Bournaud-Salinas in
Google Scholar
PubMed
Search for other papers by Myriam Decaussin-Petrucci in
Google Scholar
PubMed
Laboratoire Health Services and Performance Research (EA 7425 HESPER), Université Claude Bernard Lyon 1, Villeurbanne, France
Search for other papers by Jean Christophe Lifante in
Google Scholar
PubMed
Search for other papers by Agnès Perrin in
Google Scholar
PubMed
Search for other papers by Jean-Louis Peix in
Google Scholar
PubMed
CarMeN Laboratory, Université Claude-Bernard Lyon 1, Inserm U1060, INRA U1397, INSA Lyon, IMBL, Villeurbanne, France
Search for other papers by Philippe Moulin in
Google Scholar
PubMed
Search for other papers by Geneviève Sassolas in
Google Scholar
PubMed
Search for other papers by Michel Pugeat in
Google Scholar
PubMed
Registre des Cancers Thyroïdiens du Département du Rhône, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France
Laboratoire Health Services and Performance Research (EA 7425 HESPER), Université Claude Bernard Lyon 1, Villeurbanne, France
Search for other papers by Françoise Borson-Chazot in
Google Scholar
PubMed
Introduction: Recent guidelines of the American Thyroid Association (ATA) suggest that a lobectomy may be sufficient to treat low- to intermediate-risk patients with thyroid tumors ≤40 mm, without extrathyroidal extension or lymph node metastases. The present study aimed to evaluate long-term recurrence after lobectomy for differentiated thyroid cancer and to analyze factors associated with recurrence. Methods: In this retrospective cohort study, patients who underwent a lobectomy for thyroid cancer in a tertiary center between 1970 and 2010 were included. The outcome was the proportion of pathology-confirmed thyroid cancer recurrence, assessed in the whole cohort or in subgroups according to tumor size (≤ or >40 mm). Results: A total of 295 patients were included, and these were followed-up for a mean (standard deviation, SD) 19.1 (7.8) years (5,649 patient-years); 61 (20.7%) were male and the mean (SD) age at diagnosis was 39.7 (12) years. Histological subtype was papillary in 263 (89.2%) patients and mean cancer size was 22.9 (16.9) mm. According to the 2015 ATA guidelines, 271 (91.9%) cancers had a low risk of recurrence and 24 (8.1%) an intermediate risk. A reoperation was performed in 54 patients (18.3%) and recurrence was confirmed in 40 (13.6%), diagnosed for 55% of cases more than 10 years after their initial surgery. Among recurrent patients, 14 (4.8% of the cohort) were operated for a contralateral papillary thyroid microcarcinoma and 26 (8.8% of the cohort) for a locoregional or metastatic recurrence. Non-suspicious nodular recurrences were monitored without reoperation in 53 (18.0%) patients. At the end of follow-up, 282 (95.6%) patients were in remission. Tumors with locoregional or metastatic recurrence were more frequent among tumors with aggressive histology (19.2 vs. 4.1%, p = 0.015) and of intermediate risk category (28.6 vs. 7.1%, p = 0.018). Tumors >40 mm, which would have been treated by thyroidectomy according to the 2015 ATA guidelines criteria, were found in 34 (11.5%) patients and were associated with a higher frequency of recurrence (20.6 vs. 7.3%, p = 0.024) and less remission (85.3 vs. 96.9%, p = 0.001). Conclusion: The outcome of thyroid cancer treated by lobectomy is very good, particularly for cancer ≤40 mm. A prolonged follow-up is required due to the risk of late recurrence.